Peptides in Receptor-Mediated Radiotherapy: From Design to the Clinical Application in Cancers - CRLC Val d'Aurelle - Paul Lamarque Accéder directement au contenu
Article Dans Une Revue Frontiers in Oncology Année : 2013

Peptides in Receptor-Mediated Radiotherapy: From Design to the Clinical Application in Cancers

Résumé

(1) Background: Nanomedicine has recently emerged as a new area of research, particularly to fight cancer. In this field, we were interested in the vectorization of pepstatin A, a peptide which does not cross cell membranes, but which is a potent inhibitor of cathepsin D, an aspartic protease particularly overexpressed in breast cancer. (2) Methods: We studied two kinds of nanoparticles. For pepstatin A delivery, mesoporous silica nanoparticles with large pores (LPMSNs) and hollow organosilica nanoparticles (HOSNPs) obtained through the sol–gel procedure were used. The nanoparticles were loaded with pepstatin A, and then the nanoparticles were incubated with cancer cells. (3) Results: LPMSNs were monodisperse with 100 nm diameter. HOSNPs were more polydisperse with diameters below 100 nm. Good loading capacities were obtained for both types of nanoparticles. The nanoparticles were endocytosed in cancer cells, and HOSNPs led to the best results for cancer cell killing. (4) Conclusions: Mesoporous silica-based nanoparticles with large pores or cavities are promising for nanomedicine applications with peptides.
Fichier principal
Vignette du fichier
Lozza_2013.pdf (823.79 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
licence : CC BY - Paternité

Dates et versions

hal-03824440 , version 1 (02-06-2023)

Licence

Paternité

Identifiants

Citer

Catherine Lozza, Isabelle Navarro-Teulon, André Pèlegrin, Jean-Pierre Pouget, Eric Vivès. Peptides in Receptor-Mediated Radiotherapy: From Design to the Clinical Application in Cancers. Frontiers in Oncology, 2013, 3 (2), pp.332. ⟨10.3389/fonc.2013.00247⟩. ⟨hal-03824440⟩
15 Consultations
10 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More